A detailed history of Lyell Wealth Management, LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lyell Wealth Management, LP holds 7,230 shares of GILD stock, worth $642,168. This represents 0.06% of its overall portfolio holdings.

Number of Shares
7,230
Previous 7,230 -0.0%
Holding current value
$642,168
Previous $496,000 22.18%
% of portfolio
0.06%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$71.58 - $87.29 $1,073 - $1,309
-15 Reduced 0.21%
7,230 $529,000
Q4 2023

Feb 02, 2024

SELL
$73.27 - $83.09 $4,762 - $5,400
-65 Reduced 0.89%
7,245 $586,000
Q2 2023

Aug 04, 2023

SELL
$76.01 - $86.7 $380 - $433
-5 Reduced 0.07%
7,310 $563,000
Q1 2023

May 03, 2023

BUY
$77.31 - $88.08 $6,571 - $7,486
85 Added 1.18%
7,315 $606,000
Q4 2022

Jan 24, 2023

BUY
$62.32 - $89.47 $14,333 - $20,578
230 Added 3.29%
7,230 $0
Q3 2022

Oct 24, 2022

SELL
$59.54 - $68.01 $14,706 - $16,798
-247 Reduced 3.41%
7,000 $432,000
Q1 2022

May 04, 2022

SELL
$57.92 - $72.58 $11,757 - $14,733
-203 Reduced 2.72%
7,247 $431,000
Q4 2021

Feb 08, 2022

SELL
$64.88 - $73.64 $16,739 - $18,999
-258 Reduced 3.35%
7,450 $541,000
Q3 2021

Nov 10, 2021

BUY
$67.69 - $73.03 $7,039 - $7,595
104 Added 1.37%
7,708 $538,000
Q2 2021

Aug 09, 2021

BUY
$63.47 - $69.35 $9,774 - $10,679
154 Added 2.07%
7,604 $524,000
Q1 2021

May 07, 2021

BUY
$60.0 - $68.46 $27,000 - $30,806
450 Added 6.43%
7,450 $481,000
Q3 2020

Nov 04, 2020

SELL
$62.1 - $78.08 $7,762 - $9,760
-125 Reduced 1.75%
7,000 $442,000
Q1 2020

May 11, 2020

BUY
$62.63 - $80.22 $7,828 - $10,027
125 Added 1.79%
7,125 $533,000
Q3 2018

Oct 30, 2018

BUY
$71.28 - $78.92 $498,960 - $552,440
7,000 New
7,000 $540,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Lyell Wealth Management, LP Portfolio

Follow Lyell Wealth Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lyell Wealth Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lyell Wealth Management, LP with notifications on news.